Targeting the Future of Pancreatic Cancer Care: RAS, Biomarkers, and Emerging Therapies

In this episode, Dr Paul E. Oberstein, Dr Andrew H. Ko, and Dr Efrat Dotan discuss recent advances in pancreatic cancer, including: • The evolving role of chemotherapy • Utility of tumor treating fields for the treatment of locally advanced pancreatic adenocarcinoma • Emerging RAS-targeted strategies and novel approaches for CLDN18.2- and MTAP-altered disease • The potential impact of these developments on future treatment sequencing and supportive care  Get access to all of our new podcasts by subscribing to the Decera Clinical Education Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters: Paul E. Oberstein, MD, MS Section Chief, GI Oncology Associate Professor of Medicine Co-Director, KRAS Excellence Initiative Perlmutter Cancer Center NYU Langone Health New York, New York Andrew H. Ko, MD, FASCO Professor of Medicine and Associate Chief Division of Hematology/Oncology University of California San Francisco San Francisco, California Efrat Dotan, MD, MTR Clinical Professor of Medicine (Hematology/Oncology) Executive Medical Director, Penn Medicine, Ann B. Barshinger Cancer Center Penn Center for Cancer Care Innovation, Abramson Cancer Center University of Pennsylvania Philadelphia, Pennsylvania Link to full program:  https://bit.ly/44HPR1U Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com (https://pcm.adswizz.com) for information about our collection and use of personal data for advertising.